Cargando…
Formulary Review of Therapeutic Alternatives for Atopic Dermatitis: Focus on Pimecrolimus
OBJECTIVES: Atopic dermatitis (AD), often called eczema, is characterized by intense pruritus, erythema, dry skin, and inflammation. The condition is chronic and relapsing, and often occurs in patients with a family history of the atopic triad (asthma, allergic rhinitis, and AD). Use of topical ster...
Autor principal: | Weinberg, Jeffery M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437615/ https://www.ncbi.nlm.nih.gov/pubmed/15667233 http://dx.doi.org/10.18553/jmcp.2005.11.1.56 |
Ejemplares similares
-
Administrative Claims Analysis of Utilization and Costs of Care in Health Plan Members With Atopic Dermatitis Who Had Prior Use of a Topical Corticosteroid and Who Initiate Therapy With Pimecrolimus or Tacrolimus
por: Delea, Thomas E., et al.
Publicado: (2007) -
Health Plan Budget Impact Analysis for Pimecrolimus
por: Chang, Jane, et al.
Publicado: (2005) -
Effect of Patient Notification of Formulary Change on Formulary Adherence
por: Delate, Thomas, et al.
Publicado: (2005) -
Alternate Financial Incentives in Multi-tiered Formulary Systems to Improve Accountability for Outcomes
por: Chung, Richard S., et al.
Publicado: (2003) -
Critical Review of Prasugrel for Formulary Decision Makers
por: Schafer, Jeremy
Publicado: (2009)